IOVA
IOVA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
3
$107K
Insider Sales
0
$0
Total Volume
$107K
7 transactions
Net Activity
+$107K
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •Cluster buying: 3 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
P - Purchase Insiders
$11.42B total
Kirby Daniel Gordon
Chief Commercial Officer
$55K total
Vogt Frederick G
Interim CEO, GC
$42K total
Puri Raj K.
Chief Regulatory Officer
$10K total
Quick Actions
IOVA has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at IOVA (IOVA) engaged in a total of 7 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 0 were sales. The total volume of insider trading reached $107K.
The net insider activity for IOVA shows a net buying bias of $107K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 374.6K shares valued at $9.37B on May 14, 2025.
Is 50% Crash Risk For Iovance Stock Real?
Can Iovance Stock Fall 50%?
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
IOVA Stock: Can Cell Therapy Deliver Commercial Growth for Iovance?
Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook
Iovance: Buy Now Before Many Growth Catalysts Kick In (NASDAQ:IOVA)
FAQs About IOVA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for IOVA.